The U.S.-Mexico-China Manufacturing Triangle – The Globalist


1

Mexican manufacturing wages remain roughly 40% lower than Chinese manufacturing wages and 88% lower than those in the United States.

2

There are now more than 200 Chinese manufacturing and infrastructure investments in Mexico.

3

Roughly 20% of the value of Mexican exports to the United States consists of Chinese content.

4

Mexico now has a sizeable trade deficit with China, even though it has a large bilateral trade surplus with the United States.  This is in part due to the duty-free export platform it provides into the United States.

5

In January 2026, there were 12.59 American manufacturing workers compared to 12.74 million in February 2020, before COVID-related manufacturing job losses began.

6

Notably, by December 2024, at the end of the Biden administration, U.S. manufacturing employment had climbed again to reach 12.69 million.

7

However, in the first 11 months of Trump’s second term (February–December 2025), the United States has lost 91,000 manufacturing jobs.

8

Meanwhile, Mexico has added roughly a total of 700,000 manufacturing jobs since 2020.

9

From 2022 to 2024, U.S. auto sector employment averaged more than one million jobs, a level not seen since the early 2000s.

10

However, in the second half of 2025, U.S. auto industry employment began to decline to a level of 951,000 auto manufacturing jobs in December 2025.

Free Training

Source link

FDA proposals to speed up trials, generics for U.S. pharma firms


WASHINGTON — The Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs.  

FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers.


STAT Plus: White House proposes 12% cut to federal health agencies in 2027 budget request

The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. For example, many of the brand drugmakers that struck deals to lower U.S. prices also promised to increase domestic manufacturing, under the threat of tariffs.

STAT+ Exclusive Story

STAT+





This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Free Training

Source link